Patent · US Active

Molecular subtyping, prognosis and treatment of prostate cancer

US9568483B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

Cornell University · IT

Inventors

Mark A. Rubin · New York, US
Himisha Beltran · New York, US

Key dates

Filing date	Mar 28, 2012
Grant date	Feb 14, 2017
Priority date	—
Expiry date	Mar 28, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/91215
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.